Cardiac Biotech Solutions Inc.
CBSC
Rank in Stocks
#30209
Operating globally through its international subsidiaries, Cardiac Biotech... Operating globally through its international subsidiaries, Cardiac Biotech Solutions Inc. delivers advanced products and services for non-invasive, mobile cardiac monitoring. The company's portfolio includes FDA and CE-approved EKG devices, sophisticated cloud-based data acquisition software, and intuitive smartphone applications compatible with both iOS and Android platforms. These solutions are designed to boost patient engagement for individuals prone to irregular heart rhythms, simultaneously providing medical professionals with highly accurate diagnostic insights. Furthermore, its wholly owned U.S. subsidiary, My-Cardia (USA), Inc., focuses on creating wearable ECG recording devices that patients can utilize in an ambulatory setting for periods extending up to 30 days.
Share Price
$0.0345
Last synced: 2026-11-09
Market Cap
$5.71M
Change (1 day)
-1.43%
Change (1 year)
-9.21%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Cardiac Biotech Solutions Inc. (CBSC)
Category
Healthcare
Operating Margin for Cardiac Biotech Solutions Inc. (CBSC)
Operating Margin as of November 2026 TTM: -725.51%
According to Cardiac Biotech Solutions Inc.'s latest financial reports, its current operating margin (TTM) is -725.51%. At the end of 2025 the company had an operating margin of -3,207.45%.
Operating Margin history for Cardiac Biotech Solutions Inc. from 2017 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -725.51% | -77.38% |
| 2025 | -3,207.45% | 171.47% |
| 2024 | -1,181.52% | -53.68% |
| 2023 | -2,550.71% | 3.04% |
| 2022 | -2,475.42% | -72.71% |
| 2021 | -9,071.50% | 1,006.69% |
| 2020 | -819.70% | 668.59% |
| 2019 | -106.65% | -91.89% |
| 2018 | -1,314.88% | 17.18% |
| 2017 | -1,122.15% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 28.37% | -100.04% |
US
|
|
| 12.36% | -100.02% |
FR
|
|
| 9.83% | -100.01% |
US
|
|
| 31.11% | -100.04% |
JP
|
|
| 9.87% | -100.01% |
CH
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Cardiac Biotech Solutions Inc.'s operating margin
What is Cardiac Biotech Solutions Inc.'s operating margin?
Cardiac Biotech Solutions Inc.'s operating margin is -725.51%, as of Nov 2026.
What was Cardiac Biotech Solutions Inc.'s operating margin in 2025?
In 2025, Cardiac Biotech Solutions Inc.'s operating margin was -3,207.45%, compared with -1,181.52% in 2024.
How has Cardiac Biotech Solutions Inc.'s operating margin changed since 2020?
From 2020 to 2025, Cardiac Biotech Solutions Inc.'s operating margin was highest in 2020 (-819.70%) and lowest in 2021 (-9,071.50%).
How does Cardiac Biotech Solutions Inc.'s operating margin compare with similar companies?
Cardiac Biotech Solutions Inc.'s operating margin (-725.51%) is lower than that of all 5 similar companies listed above. The highest among them is HOYA Corporation, with 31.11%.